

# Leandro Kasuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7822023/publications.pdf>

Version: 2024-02-01

56  
papers

1,529  
citations

377584

21  
h-index

371746

37  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1421  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Energy Availability Interferes With Exercise-Associated Bone Effects in Female Long-Distance Triathletes as Detected by HR-pQCT. <i>Journal of Clinical Densitometry</i> , 2022, 25, 160-167.	0.5	7
2	The Future of Somatostatin Receptor Ligands in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 297-308.	1.8	35
3	A prospective study on the efficacy of oral estrogen in female patients with acromegaly. <i>Pituitary</i> , 2022, 25, 433-443.	1.6	5
4	Pituitary MRI Standard and Advanced Sequences: Role in the Diagnosis and Characterization of Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1431-1440.	1.8	6
5	Innovative therapeutics in acromegaly. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101679.	2.2	6
6	Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 212-230.	0.3	5
7	Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2047-2056.	1.8	27
8	Apoplexy in sporadic pituitary adenomas: a single referral center experience and AIP mutation analysis. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 295-304.	0.3	1
9	New and emerging pharmacological treatment options for acromegaly. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1615-1623.	0.9	6
10	GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil. <i>Endocrine</i> , 2021, 74, 146-154.	1.1	3
11	The Glittre Activities of Daily Living Test in patients with acromegaly: Associations with hand function and health-related quality of life. <i>Journal of Back and Musculoskeletal Rehabilitation</i> , 2021, 34, 441-451.	0.4	4
12	Microarchitectural parameters and bone mineral density in patients with tumour-induced osteomalacia by HR-pQCT and DXA. <i>Clinical Endocrinology</i> , 2021, 95, 587-594.	1.2	8
13	Growth hormone-releasing hormone-secreting pulmonary neuroendocrine tumor associated with pituitary hyperplasia and somatotropinoma. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 648-663.	0.3	2
14	gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. <i>Cancers</i> , 2021, 13, 4857.	1.7	10
15	Definition and diagnosis of aggressive pituitary tumors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 203-208.	2.6	33
16	Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas. <i>Clinical Endocrinology</i> , 2020, 92, 145-149.	1.2	16
17	Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 475-486.	1.2	14
18	Cyclin A in nonfunctioning pituitary adenomas. <i>Endocrine</i> , 2020, 70, 380-387.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Novel therapies for acromegaly. <i>Endocrine Connections</i> , 2020, 9, R274-R285.	0.8	8
20	Determinants of morbidities and mortality in acromegaly. <i>Archives of Endocrinology and Metabolism</i> , 2020, 63, 630-637.	0.3	39
21	Reply to "Predictors of surgical outcome and early criteria of remission in acromegaly" some controversial issues. <i>Endocrine</i> , 2019, 63, 190-191.	1.1	2
22	Brazilian multicenter study on pegvisomant treatment in acromegaly. <i>Archives of Endocrinology and Metabolism</i> , 2019, 63, 328-336.	0.3	16
23	Physical exercise improves functional capacity and quality of life in patients with acromegaly: a 12-week follow-up study. <i>Endocrine</i> , 2019, 66, 301-309.	1.1	11
24	Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. <i>Cancers</i> , 2019, 11, 1439.	1.7	30
25	The effectiveness of a therapist-oriented home rehabilitation program for a patient with acromegaly: A case study. <i>Journal of Bodywork and Movement Therapies</i> , 2019, 23, 634-642.	0.5	4
26	Clinical and functional variables can predict general fatigue in patients with acromegaly: an explanatory model approach. <i>Archives of Endocrinology and Metabolism</i> , 2019, 63, 235-240.	0.3	0
27	Management of pituitary incidentaloma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101268.	2.2	21
28	Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. <i>Scientific Reports</i> , 2019, 9, 1122.	1.6	21
29	Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. <i>Endocrine Reviews</i> , 2019, 40, 268-332.	8.9	226
30	Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. <i>Clinical Endocrinology</i> , 2018, 88, 889-895.	1.2	21
31	Predictors of surgical outcome and early criteria of remission in acromegaly. <i>Endocrine</i> , 2018, 60, 415-422.	1.1	61
32	Molecular evidence and clinical importance of $\beta$ -arrestins expression in patients with acromegaly. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2110-2116.	1.6	18
33	MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. <i>European Journal of Endocrinology</i> , 2018, 178, R89-R100.	1.9	56
34	Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain. <i>Pituitary</i> , 2017, 20, 349-357.	1.6	23
35	The genetic background of acromegaly. <i>Pituitary</i> , 2017, 20, 10-21.	1.6	65
36	AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation. <i>Endocrine Connections</i> , 2017, 6, 914-925.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1381-1387.	1.8	14
38	Balance Control and Peripheral Muscle Function in Aging: A Comparison Between Individuals with Acromegaly and Healthy Subjects. <i>Journal of Aging and Physical Activity</i> , 2017, 25, 218-227.	0.5	20
39	Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response. <i>Archives of Endocrinology and Metabolism</i> , 2016, 60, 479-485.	0.3	19
40	Parameters of knee isokinetic dynamometry in individuals with acromegaly: Association with growth hormone levels and general fatigue. <i>Isokinetics and Exercise Science</i> , 2016, 24, 331-340.	0.2	12
41	Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients. <i>Pituitary</i> , 2016, 19, 375-380.	1.6	4
42	Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. <i>Pituitary</i> , 2016, 19, 582-589.	1.6	36
43	Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. <i>Pituitary</i> , 2016, 19, 235-247.	1.6	93
44	Evidence-based guidelines in acromegaly: implications on the clinic. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 171-175.	1.2	0
45	What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients?. <i>Journal of Physical Therapy Science</i> , 2015, 27, 719-724.	0.2	11
46	Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas. <i>PLoS ONE</i> , 2015, 10, e0117107.	1.1	59
47	Low risk of coronary artery disease in patients with acromegaly. <i>Endocrine</i> , 2015, 50, 749-755.	1.1	21
48	Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4447-4455.	1.8	51
49	Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, Tj ETQq1 1 0.784314,rgBT /Overlock 1 3.2 72		
50	Posture and balance control in patients with acromegaly: Results of a cross-sectional study. <i>Gait and Posture</i> , 2014, 40, 154-159.	0.6	18
51	Cabergoline treatment in acromegaly: cons. <i>Endocrine</i> , 2014, 46, 220-225.	1.1	31
52	Acromegalic patients lost to follow-up: a pilot study. <i>Pituitary</i> , 2013, 16, 245-250.	1.6	20
53	Novel pathway for somatostatin analogs in patients with acromegaly. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 238-246.	3.1	126
54	Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. <i>European Journal of Endocrinology</i> , 2013, 169, 217-223.	1.9	55

#	ARTICLE	IF	CITATIONS
55	On the Functional Capacity and Quality of Life of Patients with Acromegaly: Are They Candidates for Rehabilitation Programs?. <i>Journal of Physical Therapy Science</i> , 2013, 25, 1497-1501.	0.2	18
56	Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2012, 56, 501-506.	1.3	13